Markman M
Cleveland Clinic Cancer Center and the Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, OH 44195, USA.
Semin Oncol. 1998 Jun;25(3):356-60.
During the past decade, intraperitoneal chemotherapy has evolved from a theoretical concept into a rational therapeutic strategy for a select group of individuals with ovarian cancer. Patients who may potentially benefit from this approach include those with small volume intraperitoneal disease at the initiation of initial chemotherapy and individuals with microscopic and very small volume macroscopic cancer after the completion of front-line systemic treatment. Further exploration to define an ultimate role for regional antineoplastic drug delivery in the management of ovarian cancer is warranted.
在过去十年中，腹腔内化疗已从一个理论概念发展成为针对特定卵巢癌患者群体的合理治疗策略。可能从这种方法中潜在获益的患者包括初始化疗开始时腹腔内病灶较小的患者，以及一线全身治疗完成后有微小和极微小体积宏观癌灶的患者。有必要进一步探索区域抗肿瘤药物递送在卵巢癌治疗中的最终作用。
